Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17133489 | TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS | December 2020 | March 2024 | Allow | 39 | 1 | 1 | No | No |
| 17092043 | SLC45A2 PEPTIDES FOR IMMUNOTHERAPY | November 2020 | June 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17026447 | PD-1 Peptide Inhibitors | September 2020 | December 2023 | Abandon | 39 | 1 | 1 | No | No |
| 17017358 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | September 2020 | March 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17017117 | NK CELL-DIRECTED CHIMERIC PROTEINS | September 2020 | July 2022 | Abandon | 22 | 3 | 1 | No | No |
| 17015658 | PD-1 Peptide Inhibitors | September 2020 | March 2023 | Allow | 31 | 0 | 1 | Yes | No |
| 16979146 | A METHOD OF DETECTING MAGEA4 | September 2020 | March 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17003750 | PLASMA MEMBRANE CITRATE TRANSPORTER FOR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER | August 2020 | November 2024 | Allow | 50 | 4 | 0 | Yes | No |
| 16984615 | METHODS AND KITS FOR ANALYSIS OF HMGB1 ISOFORMS | August 2020 | July 2023 | Abandon | 36 | 1 | 1 | No | No |
| 16928293 | METHODS FOR DETECTING AND FOR TREATING PANCREATIC CANCER | July 2020 | April 2024 | Allow | 45 | 3 | 0 | Yes | No |
| 16915772 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | June 2020 | October 2020 | Allow | 4 | 1 | 0 | Yes | No |
| 16915420 | METHOD OF TREATING WITH A PEPTIDE | June 2020 | October 2020 | Allow | 3 | 1 | 0 | Yes | No |
| 16899907 | PLASMA BIOMARKER FOR OVARIAN CANCER | June 2020 | May 2023 | Abandon | 35 | 1 | 1 | Yes | No |
| 16900194 | METHODS AND COMPOSITIONS FOR ASSESSING GERMLINE RISK OF CANCER | June 2020 | January 2023 | Allow | 31 | 2 | 1 | No | No |
| 16895395 | R-Spondin Translocations and Methods Using the Same | June 2020 | May 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16887765 | METHOD OF TREATING WITH A PEPTIDE | May 2020 | November 2020 | Allow | 5 | 1 | 0 | Yes | No |
| 16768001 | METHOD FOR CLASSIFYING CANCER PATIENTS INTO APPROPRIATE HEPATOCELLULAR CARCINOMA TREATMENT GROUPS AND COMPOUNDS FOR TREATING THE PATIENT | May 2020 | December 2024 | Allow | 54 | 3 | 1 | Yes | No |
| 16814532 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | March 2020 | May 2021 | Allow | 14 | 1 | 0 | No | No |
| 16644106 | METHODS FOR IDENTIFYING MYELOMA TUMOR-INITIATING CELLS AND TARGETED THERAPY | March 2020 | July 2024 | Abandon | 53 | 3 | 1 | Yes | No |
| 16773192 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY | January 2020 | October 2022 | Abandon | 33 | 4 | 1 | Yes | Yes |
| 16752537 | COMBINATION THERAPY WITH A BET INHIBITOR, A BCL-2 INHIBITOR AND AN ANTI-CD20 ANTIBODY | January 2020 | August 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16751145 | METHODS OF IDENTIFYING INDIVIDUALS AT INCREASED RISK OF LUNG CANCER | January 2020 | April 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16632402 | METHODS AND KITS FOR PREDICTING THE SENSITIVITY OF A SUBJECT SUFFERING OF RENAL CANCER TO SUNITINIB | January 2020 | May 2023 | Abandon | 39 | 1 | 0 | No | No |
| 16727777 | SHON AS A PROGNOSTIC BIOMARKER FOR CANCER AND AS A PREDICTOR OF RESPONSE TO ENDOCRINE THERAPY | December 2019 | March 2025 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 16625697 | BIOMARKER FOR DETECTING COLORECTAL CANCER | December 2019 | November 2024 | Abandon | 59 | 3 | 1 | No | No |
| 16615423 | COMBINATION OF MARKERS FOR DIAGNOSING CANCER | November 2019 | March 2023 | Allow | 40 | 2 | 1 | No | Yes |
| 16686390 | IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS | November 2019 | December 2022 | Abandon | 37 | 1 | 1 | No | No |
| 16612485 | METHODS AND COMPOSITIONS OF USE OF CD8+ TUMOR INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF | November 2019 | October 2024 | Allow | 59 | 6 | 1 | Yes | No |
| 16673619 | METHOD OF TREATING WITH A PEPTIDE | November 2019 | March 2020 | Allow | 4 | 1 | 0 | Yes | No |
| 16609721 | USE OF DIANHYDROGALACTITOL OR ANALOGS AND DERIVATIVES IN COMBINATION WITH VEGF INHIBITORS TO TREAT CANCER | October 2019 | February 2024 | Abandon | 52 | 5 | 0 | No | No |
| 16664543 | YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA | October 2019 | October 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16662399 | Anti-CD28 Humanized Antibodies Formulated for Administration to Humans | October 2019 | March 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16607662 | DETECTION AND TARGETING OF TUMOR-PROMOTING NEUTROPHILS | October 2019 | February 2023 | Abandon | 40 | 3 | 1 | No | No |
| 16653268 | DIAGNOSTIC METHODS FOR LIVER DISORDERS | October 2019 | January 2024 | Abandon | 51 | 4 | 0 | Yes | No |
| 16494223 | DETECTION, QUANTIFICATION AND/OR ISOLATION OF CIRCULATING TUMOR CELLS BASED ON THE EXPRESSION OF CD321 MARKER | September 2019 | June 2024 | Allow | 57 | 4 | 1 | Yes | No |
| 16563740 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | September 2019 | February 2020 | Allow | 5 | 1 | 0 | No | No |
| 16563704 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | September 2019 | February 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16558455 | MEST AS BIOMARKER FOR CANCER DIAGNOSIS AND PROGNOSIS AND METHOD FOR USING THEREOF | September 2019 | April 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16557234 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | August 2019 | May 2023 | Abandon | 45 | 1 | 0 | No | No |
| 16552836 | METHOD OF TREATING BREAST CANCER | August 2019 | August 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16488083 | ASSAY FOR DETECTION OF EARLY STAGE PANCREATIC CANCER | August 2019 | February 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16535855 | ANTI-CD22 ANTIGEN BINDING MOLECULES TO TREAT LUNG CANCER AND PROSTATE CANCER | August 2019 | July 2023 | Abandon | 47 | 3 | 0 | Yes | No |
| 16527770 | PROTECTION AGAINST STRESS-MEDIATED DAMAGE FROM IONIZING RADIATION | July 2019 | September 2021 | Allow | 26 | 1 | 0 | No | No |
| 16523096 | DETECTION OF HISTONE MODIFICATION IN CELL-FREE NUCLEOSOMES | July 2019 | May 2022 | Abandon | 33 | 1 | 0 | No | No |
| 16520746 | PANCREATIC CANCER TARGETS AND USES THEREOF | July 2019 | August 2022 | Abandon | 37 | 1 | 1 | No | No |
| 16511935 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | July 2019 | October 2022 | Allow | 39 | 1 | 1 | No | No |
| 16503901 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | July 2019 | September 2019 | Allow | 2 | 0 | 0 | Yes | No |
| 16503882 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | July 2019 | August 2019 | Allow | 2 | 0 | 0 | Yes | No |
| 16446526 | METHOD FOR DISCRIMINATING BETWEEN PROSTATE CANCER AND A BENIGN PROSTATE DISEASE | June 2019 | August 2022 | Abandon | 38 | 2 | 0 | No | No |
| 16443517 | RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOF | June 2019 | June 2020 | Abandon | 12 | 1 | 0 | No | No |
| 16465729 | METHODS AND COMPOSITIONS FOR DIAGNOSING RENAL CELL CARCINOMA | May 2019 | October 2022 | Abandon | 41 | 2 | 1 | No | No |
| 16425607 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | May 2019 | July 2019 | Allow | 2 | 0 | 0 | No | No |
| 16408510 | BINDING PROTEINS AND CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING GASP-I GRANULES AND USES THEREOF | May 2019 | June 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16344985 | IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY HDAC INHIBITORS | April 2019 | August 2023 | Allow | 51 | 2 | 1 | No | Yes |
| 16387300 | METHOD FOR BLOCKING STRESS-INDUCED TUMOR PROGRESSION | April 2019 | January 2022 | Allow | 33 | 1 | 1 | Yes | No |
| 16384428 | METHODS OF TREATING AND PREVENTING MELANOMA WITH S-EQUOL | April 2019 | October 2022 | Abandon | 42 | 2 | 1 | Yes | No |
| 16070828 | NOVEL SPECIFIC MONOCLONAL ANTIBODY TO ACETYLATED MOUSE BUBR1 AND PREPARATION METHOD THEREFOR | March 2019 | August 2021 | Allow | 37 | 1 | 0 | Yes | No |
| 16356582 | ANALYSIS OF RESPONSE TO THERAPEUTICS IN CANCER | March 2019 | November 2023 | Abandon | 56 | 4 | 1 | No | No |
| 16354689 | CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT | March 2019 | April 2021 | Allow | 25 | 0 | 0 | No | No |
| 16333590 | CELL DEATH BIOMARKER | March 2019 | May 2023 | Allow | 50 | 3 | 1 | Yes | No |
| 16331197 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | March 2019 | July 2023 | Abandon | 53 | 3 | 1 | No | No |
| 16295978 | CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT | March 2019 | February 2022 | Allow | 35 | 1 | 1 | Yes | No |
| 16292054 | SYNTHETIC PEPTIDE, RELATIVE ARTIFICIAL ANTIGEN, RELATIVE ANTI-EHD2 ANTIBODY AND PREPARATION METHOD THEREOF AND USE THEREOF | March 2019 | December 2021 | Allow | 34 | 2 | 1 | Yes | No |
| 16275111 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER | February 2019 | June 2022 | Allow | 40 | 2 | 1 | Yes | No |
| 16271235 | TREATMENT OF CANCER WITH ANTI-IL-1 ALPHA ANTIBODIES | February 2019 | February 2024 | Abandon | 60 | 2 | 0 | No | Yes |
| 16323807 | Method Relating to Evaluation of Tumor Tissue of Experimental Animal | February 2019 | February 2022 | Abandon | 37 | 0 | 1 | No | No |
| 16267647 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | February 2019 | May 2019 | Allow | 3 | 1 | 0 | No | No |
| 16323482 | CAMKK2 INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME | February 2019 | August 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16256065 | METHODS OF INHIBITING METASTASIS IN CANCER | January 2019 | October 2021 | Abandon | 33 | 1 | 1 | No | No |
| 16319948 | METHODS OF TREATEMENT OF CANCER DISEASE BY TARGETTING TUMOR ASSOCIATED MACROPHAGE | January 2019 | May 2021 | Abandon | 28 | 0 | 1 | No | No |
| 16240474 | METHODS FOR TREATING COLORECTAL AND METASTATIC COLORECTAL CANCERS | January 2019 | December 2022 | Abandon | 47 | 3 | 1 | Yes | No |
| 16315275 | VINFLUNINE AND PD1 AND/OR PDL1 INHIBITOR AS PHARMACEUTICAL COMBINATION | January 2019 | February 2022 | Abandon | 38 | 2 | 1 | Yes | No |
| 16312716 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH SIGLEC-9 ACTIVITY MODULATORS | December 2018 | August 2021 | Abandon | 32 | 1 | 1 | Yes | No |
| 16223470 | COMPOSITIONS AND METHODS COMPRISING DIGITAL SIGNATURES TO PREDICT RESPONSE AND RESISTANCE TO TARGETED THERAPY AND IMMUNOTHERAPY | December 2018 | July 2022 | Allow | 43 | 2 | 1 | Yes | No |
| 16223091 | SYSTEM AND METHOD FOR THE TREATMENT OF DISEASE USING A HYPERSPECIFIC MODIFIED PROTEIN SYSTEM | December 2018 | May 2025 | Abandon | 60 | 7 | 1 | Yes | No |
| 16207758 | ABT-165 IN COMBINATION WITH FOLINIC ACID, 5-FLUOROURACIL, AND IRINOTECAN FOR THE TREATMENT OF CANCERS | December 2018 | September 2021 | Abandon | 34 | 1 | 1 | No | No |
| 16306380 | ANTI-PD-1 ANTIBODY FOR USE IN A METHOD OF TREATING A TUMOR | November 2018 | August 2022 | Abandon | 45 | 3 | 0 | Yes | No |
| 16301019 | Methods for Predicting the Usefulness of Proteins or Protein Fragments for Immunotherapy | November 2018 | July 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16186245 | TREATMENT OF THERAPY-RESISTANT HER-2 POSITIVE BREAST CANCER | November 2018 | November 2022 | Abandon | 48 | 2 | 1 | No | No |
| 16180385 | DISCOVERY AND VALIDATION OF CANCER BIOMARKERS USING A PROTEIN ANALYSIS METHODOLOGY TO ANALYZE SPECIMENS | November 2018 | July 2023 | Abandon | 56 | 2 | 1 | No | No |
| 16167656 | Immunotherapy against melanoma and other cancers | October 2018 | May 2019 | Allow | 7 | 1 | 0 | No | No |
| 16165121 | Immunotherapy against melanoma and other cancers | October 2018 | June 2019 | Allow | 8 | 1 | 0 | No | No |
| 16165275 | Immunotherapy against melanoma and other cancers | October 2018 | May 2019 | Allow | 7 | 1 | 0 | No | No |
| 16165116 | Immunotherapy against melanoma and other cancers | October 2018 | June 2019 | Allow | 8 | 1 | 0 | No | No |
| 16162333 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | October 2018 | January 2020 | Allow | 15 | 3 | 0 | Yes | No |
| 16093180 | PROGNOSIS OF SEROUS OVARIAN CANCER USING BIOMARKERS | October 2018 | September 2021 | Abandon | 35 | 1 | 1 | No | No |
| 16092798 | COMPOSITIONS AND METHODS FOR SCREENING, MONITORING AND TREATING GASTROINTESTINAL DISEASES | October 2018 | December 2021 | Abandon | 38 | 2 | 1 | Yes | No |
| 16092168 | MACROPHAGE STIMULATION IN CD47 BLOCKADE THERAPY | October 2018 | December 2022 | Abandon | 50 | 4 | 1 | Yes | No |
| 16090855 | METHODS AND KITS FOR PREDICTING THE SENSITIVITY OF A SUBJECT SUFFERING OF RENAL CANCER TO CANCER TREATMENT | October 2018 | June 2022 | Abandon | 45 | 3 | 1 | Yes | No |
| 16141911 | ANTI-BAG3 ANTIBODIES FOR THERAPEUTIC USE | September 2018 | June 2021 | Allow | 32 | 2 | 0 | Yes | No |
| 16138224 | RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOF | September 2018 | May 2019 | Allow | 8 | 1 | 1 | Yes | No |
| 16138212 | RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOF | September 2018 | May 2019 | Allow | 8 | 1 | 1 | No | No |
| 16138204 | RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOF | September 2018 | April 2019 | Allow | 7 | 1 | 1 | No | No |
| 16138219 | RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOF | September 2018 | March 2019 | Allow | 5 | 0 | 1 | Yes | No |
| 16132339 | THERAPEUTIC COMBINATION AND METHOD FOR TREATING CANCER | September 2018 | January 2022 | Abandon | 40 | 2 | 1 | No | No |
| 16085486 | Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics | September 2018 | February 2021 | Abandon | 29 | 0 | 1 | No | No |
| 16118038 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRPALPHA CD47 INTERACTION | August 2018 | January 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16080617 | THE USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIATE CHECKPOINT INHIBITORS | August 2018 | February 2021 | Allow | 30 | 4 | 0 | Yes | No |
| 16111894 | A METHOD OF TREATING AN NME7 EXPRESSING CANCER WITH A PEPTIDE | August 2018 | April 2023 | Allow | 55 | 4 | 1 | Yes | Yes |
| 16111862 | ANTI-NME ANTIBODY | August 2018 | November 2022 | Abandon | 50 | 3 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DENT, ALANA HARRIS.
With a 54.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DENT, ALANA HARRIS works in Art Unit 1643 and has examined 884 patent applications in our dataset. With an allowance rate of 40.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner DENT, ALANA HARRIS's allowance rate of 40.5% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DENT, ALANA HARRIS receive 2.32 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DENT, ALANA HARRIS is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.6% benefit to allowance rate for applications examined by DENT, ALANA HARRIS. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.5% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 32.5% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 55.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 54.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 72.9% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.9% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.